Disclosed herein is the use of a pharmaceutical composition in the manufacture of a medicament for the treatment of a medical condition, wherein the pharmaceutical composition comprises N-2-hydroxy-ethyl-piperazine-N-2-ethane sulfonic acid (HEPES) dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers in an amount sufficient to treat the medical condition and one or more optional excipients, diluents, extended or controlled release agents, coloring agents, preservatives or any combinations thereof, and wherein the medical condition is selected from at least one of the following: SSRI discontinuation syndrome one or more neurodegenerative diseases one or more demyelination diseases or both one or more neurological diseases one or more neuropsychiatric disorders or both, herein the one or more neurodegenerative diseases comprise Parkinsons disease, Alpers disease, Lou Gehrigs Disease Corticobasal degeneration, Creutzfeldt-Jakob disease, Frontotemporal lobar degeneration Huntingtons disease, Krabbes disease, Multiple System Atrophy, Multiple sclerosis, Picks disease, Primary lateral sclerosis, Progressive Supranuclear Palsy, Refsums disease, Sandhoff disease, Schilders disease, Spinal muscular atrophy, Steele-Richardson-Olszewski disease or any combinations thereof and post-chemotherapy cognitive impairment.
